Atossa Genetics Stock Price - ATOS

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
After Hours
Last Trade
Last $ 1.38 ▲ 0.05 (3.76%)
Company Name Stock Ticker Symbol Market Type
Atossa Genetics Inc ATOS NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.07 5.56% 1.33 1.375 1.2601 1.27 1.26 20:00:00
Bid Price Ask Price Spread Spread % News
1.11 1.51 0.40 26.49% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
603 211,734 $ 1.33 $ 282,493 110,256 0.80 - 7.39
Last Trade Time Type Quantity Stock Price Currency
19:03:22 5 $ 1.23 USD

Atossa Genetics Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 12.14M 9.13M $ -11.40M -13.99 - 8.58M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - 6.00%

more financials information »

Atossa Genetics News

Loading Messages....

Latest ATOS Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ATOS Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.441.471.191.29143,471-0.11-7.64%
1 Month1.741.77051.191.4376,546-0.41-23.56%
3 Months2.032.401.191.79115,846-0.70-34.48%
6 Months2.593.311.192.33266,592-1.26-48.65%
1 Year1.307.390.804.171,130,9770.032.31%
3 Years21.2431.200.806.621,357,421-19.91-93.74%
5 Years162.00477.000.8039.34976,011-160.67-99.18%

Atossa Genetics Description

Atossa Genetics Inc is a clinical-stage pharmaceutical company operating in the US. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The clinical-Stage Programs of the company includes delivery of therapeutics through microcatheters which delivers a number of therapeutics to the ducts in the breast, the site of the majority of early breast cancers and fulvestrant Delivered through microcatheters which delivers fulvestrant as a potential treatment of ductal carcinoma in-situ (DCIS) and breast cancer. In addition, the company involves in the process of evaluating additional potential indications of endoxifen and other therapeutic candidates to treat breast conditions, including breast cancer.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.